Hydroquinone In Treatment Of Melasma Research Articles

A split-face of dermaroller and intradermal injection with the autologous platelet rich fibrin lysate in the treatment of exogenous ocronosis: A case series

Exogenous ochronosis (EO) is a rare, cosmetically disfiguring condition, resulting from the long term use of topical hydroquinone in treatment of melasma. The studies about it are small and many of the treatments have mixed result. Autologous human platelet rich fibrin (PRF-L) is contains platelet that are purpose to release numerous growth factor that valuable in numerous dermatologic application.Platelet rich fibrin lysate used for EO has not been reported. We presented three cases with EO treated with split-face of the PRF-L applied right before dermaroller on right face and intradermal injection on the left for 8 weeks.The treatment re-apply every 2 weeks. The improvement was measuring by 10-point grading scale and dermoscopic examination, including five-point grading scale to assessment of patient satisfaction. All of three patients demonstrated significant improvementand very satisfied in 4th week of treatment. This result suggests that PRF-L can be used as of one modality for EO treatment.

The Comparison of Efficacy of Oral Finastride and Topical Hydroquinone Versus Placebo and Topical Hydroquinone in Treatment of Melasma: A Randomized Double-Blind Clinical Trial

Introduction Melasma is a common acquired illness with outbreak of brown and often symmetrical hypersegmented patches on frequently sun-exposed areas of the face (1 and 2). Melasma accounts for about 4 to 10 percent of the complaints of those visiting skin clinics and is more common among Hispani

Exogenous ochronosis: case report and literature review

Exogenous ochronosis is a rare, cosmetically disfiguring condition, resulting from the longterm use of topical hydroquinone in treatment of melasma. It manifests as gray-brown or blue-black macules in hydroquinone-exposed regions. The exact incidence of ochronosis is unknown. High rates have been reported in the South African population, and it is rare in the United States. We report the case of a patient who developed exogenous ochronosis while using topical hydroquinone. It is necessary to recognize this disorder at the earliest stage and discontinue hydroquinone immediately, as its treatment is difficult. Sun exposure facilitates the formation of exogenous ochronosis and must be strictly avoided, although it is a practical problem in the tropical climate of Brazil, particularly for those who work outdoors.